CARNA BIOSCIENCES, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2003-04-10
- Employees
- 67
- Market Cap
- -
- Website
- http://www.carnabio.com
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell MalignancyChronic Lymphocytic LeukemiaNon-Hodgkin LymphomaWaldenstrom MacroglobulinemiaFollicular LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaMantle Cell Lymphoma
- Interventions
- Drug: Docirbrutinib
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Carna Biosciences, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05602363
- Locations
- 🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath